WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the company’s proposed research collaboration with the University of Massachusetts Medical School (UMMS) has been selected to share in the first round of Cooperative Research Grants by the Massachusetts Life Sciences Center (“MLSC”).
